Clinical Trials
2 trialsNCT03745716 2025-03-18
APR-246 & Azacitidine for the Treatment of TP53 Mutant Myelodysplastic Syndromes (MDS)
Aprea Therapeutics
Phase 3 Completed
NCT06664970 2024-10-30
A Multicenter Study on the Treatment of MDS/MPN Overlap Syndrome With AZA or Rux Combined With Selinexor
Peking Union Medical College Hospital
Phase 2 Enrolling by invitation